The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Open accessAbstract
BACKGROUND: There has been uncertainty regarding the benefit of glycemic control with antidiabetic agents in prevention of diabetic macrovascular disease. Further development of novel antidiabetic agents is essential for overcoming the burden of diabetic macrovascular disease. The renal sodium glucose co-transporter 2 (SGLT2) inhibitor is a novel antihyperglycemic agent for treatment of type 2 diabetes. This work was performed to determine whether empagliflozin, a novel SGLT2 inhibitor, can ameliorate cardiovascular injury and cognitive decline in db/db mouse, a model of obesity and type 2 diabetes. METHODS: (1) Short-term experiment: The first experiment was performed to examine the effect of 7 days of empagliflozin treatment on urinary glucose excretion and urinary electrolyte excretion in db/db mice. (2) Long-term experiment: The second experiment was undertaken to examine the effect of 10 weeks of empagliflozin treatment on cardiovascular injury, vascular dysfunction, cognitive decline, and renal injury in db/db mice. RESULTS: (1) Short-term experiment: Empagliflozin administration significantly increased urinary glucose excretion, urine volume, and urinary sodium excretion in db/db mice on day 1, but did not increase these parameters from day 2. However, blood glucose levels in db/db mice were continuously decreased by empagliflozin throughout 7 days of the treatment. (2) Long-term experiment: Empagliflozin treatment caused sustained decrease in blood glucose in db/db mice throughout 10 weeks of the treatment and significantly slowed the progression of type 2 diabetes. Empagliflozin significantly ameliorated cardiac interstitial fibrosis, pericoronary arterial fibrosis, coronary arterial thickening, cardiac macrophage infiltration, and the impairment of vascular dilating function in db/db mice, and these beneficial effects of empagliflozin were associated with attenuation of oxidative stress in cardiovascular tissue of db/db mice. Furthermore, empagliflozin significantly prevented the impairment of cognitive function in db/db mice, which was associated with the attenuation of cerebral oxidative stress and the increase in cerebral brain-derived neurotrophic factor. Empagliflozin ameliorated albuminuria, and glomerular injury in db/db mice. CONCLUSIONS: Glycemic control with empagliflozin significantly ameliorated cardiovascular injury and remodeling, vascular dysfunction, and cognitive decline in obese and type 2 diabetic mice. Thus, empagliflozin seems to be potentially a promising therapeutic agent for diabetic macrovascular disease and cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another promising effect SGLT2i exert on the central nervous system was described by Lin B. et al., for empagliflozin, which significantly increased cerebral BDNF (Brain-derived neurotrophic factor) levels in db/db mice (Table 1). Moreover, this effect was accompanied by improvement in cognitive functions [31].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 3×
“Previous large clinical trials have established that strict glycemic control significantly reduces diabetic microvascular complications such as nephropathy or retinopathy [3-5].”
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 3×
“Previous large clinical trials have established that strict glycemic control significantly reduces diabetic microvascular complications such as nephropathy or retinopathy [3-5].”
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125 · cited 2×
“Macrovascular disease is the leading cause of mortality in diabetic patients and the burden of cardiovascular disease due to diabetes mellitus has gone on increasing [1,2].”
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 2×
“Furthermore, dipeptidyl-peptidase IV inhibitors, a novel class of antidiabetic agent, have been recently reported to fail to improve cardiovascular outcomes in large clinical trials [6,8,12-14].”
Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling
Takimoto, E., & Kass, D. A. (2007) · Hypertension · doi:10.1161/01.hyp.0000254415.31362.a7 · Cited by 770 · cited 1×
“Accumulating evidence [35-37] establish that hyperglycemia enhances tissue oxidative stress which plays a key role in the pathophysiology of diabetes mellitus and its complications.”
Kaneto, H., Kajimoto, Y., Miyagawa, J., Matsuoka, T., Fujitani, Y., Umayahara, Y., Hanafusa, T., Matsuzawa, Y., Yamasaki, Y., & Hori, M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2398 · Cited by 712 · cited 1×
“Accumulating evidence [35-37] establish that hyperglycemia enhances tissue oxidative stress which plays a key role in the pathophysiology of diabetes mellitus and its complications.”
Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study
Fox, C. S., Coady, S., Sorlie, P. D., D’Agostino, R. B., Pencina, M. J., Vasan, R. S., Meigs, J. B., Levy, D., & Savage, P. J. (2007) · Circulation · doi:10.1161/circulationaha.106.658948 · Cited by 656 · cited 2×
“Macrovascular disease is the leading cause of mortality in diabetic patients and the burden of cardiovascular disease due to diabetes mellitus has gone on increasing [1,2].”
Stranahan, A. M., Arumugam, T. V., Cutler, R. G., Lee, K., Egan, J. M., & Mattson, M. P. (2008) · Nature Neuroscience · doi:10.1038/nn2055 · Cited by 611
Cited by
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Targeting inflammation to treat diabetic kidney disease: the road to 2030
Rayego-Mateos, S., Rodrigues-Diez, R. R., Fernandez-Fernandez, B., Mora-Fernández, C., Marchant, V., Donate-Correa, J., Navarro-González, J. F., Ortiz, A., & Ruiz-Ortega, M. (2023) · Kidney International · doi:10.1016/j.kint.2022.10.030 · Cited by 366
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Ren, J., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021) · Physiological Reviews · doi:10.1152/physrev.00030.2020 · Cited by 370
Metadata
- Authors
- Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S.
- Affiliations
- Kumamoto University (JP)
- Venue
- Cardiovascular Diabetology
- Published
- 2014-10-26
- Volume
- 13
- Issue
- 1
- Pages
- 148-148
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC4219031
- OpenAlex
- W2124658554
- Cited by
- 423
- References
- 45
- Citations by year
- 2026: 19 · 2025: 37 · 2024: 40 · 2023: 41 · 2022: 54 · 2021: 58 · 2020: 39 · 2019: 40 · 2018: 33 · 2017: 25 · 2016: 20 · 2015: 15
- FWCI
- 16.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, SGLT2 inhibitors, type 2 diabetes, obesity, db/db mice, glycemic control, cardiovascular damage, diabetic macrovascular disease, myocardial fibrosis, vascular dysfunction, cognitive decline, oxidative stress, brain-derived neurotrophic factor, albuminuria, kidney injury, urinary glucose excretion, urinary electrolyte excretion, diabetic nephropathy
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cognition Disorders, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Obesity, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. https://app.cochat.ai/papers/10.1186/s12933-014-0148-1
- The paper
- Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014). Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-014-0148-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.